Why the study?
Does atrasentan reduce blood pressure and vascular/renal injury in mice with long-term endothelial human ET-1 overexpression?
Does atrasentan reduce blood pressure and vascular/renal injury in mice with long-term endothelial human ET-1 overexpression?
Long-term endothelial ET-1 overexpression causes sustained blood pressure elevation and vascular/renal injury via ETA receptors, which can be partially reversed by atrasentan.
No takes yet. Share an insight, caveat, or question.
Atrasentan partially mitigates ET-1 effects in this model; hypothesis-generating and should not inform clinical practice.
Coelho et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: